Dr. Cherry  Song  Do image

Dr. Cherry Song Do

800 Rose St C-246
Lexington KY 40536
859 236-6762
Medical School: Other - Unknown
Accepts Medicare: No
Participates In eRX: No
Participates In PQRS: No
Participates In EHR: No
License #: 208600000X
NPI: 1043445075
Taxonomy Codes:
208600000X 2086S0102X

Request Appointment Information

Awards & Recognitions

About Us

Practice Philosophy


Medical Malpractice Cases

None Found

Medical Board Sanctions

None Found


None Found


The Saccharomyces Genome Database Variant Viewer. - Nucleic acids research
The Saccharomyces Genome Database (SGD; is the authoritative community resource for the Saccharomyces cerevisiae reference genome sequence and its annotation. In recent years, we have moved toward increased representation of sequence variation and allelic differences within S. cerevisiae. The publication of numerous additional genomes has motivated the creation of new tools for their annotation and analysis. Here we present the Variant Viewer: a dynamic open-source web application for the visualization of genomic and proteomic differences. Multiple sequence alignments have been constructed across high quality genome sequences from 11 different S. cerevisiae strains and stored in the SGD. The alignments and summaries are encoded in JSON and used to create a two-tiered dynamic view of the budding yeast pan-genome, available at© The Author(s) 2015. Published by Oxford University Press on behalf of Nucleic Acids Research.
AGAPE (Automated Genome Analysis PipelinE) for pan-genome analysis of Saccharomyces cerevisiae. - PloS one
The characterization and public release of genome sequences from thousands of organisms is expanding the scope for genetic variation studies. However, understanding the phenotypic consequences of genetic variation remains a challenge in eukaryotes due to the complexity of the genotype-phenotype map. One approach to this is the intensive study of model systems for which diverse sources of information can be accumulated and integrated. Saccharomyces cerevisiae is an extensively studied model organism, with well-known protein functions and thoroughly curated phenotype data. To develop and expand the available resources linking genomic variation with function in yeast, we aim to model the pan-genome of S. cerevisiae. To initiate the yeast pan-genome, we newly sequenced or re-sequenced the genomes of 25 strains that are commonly used in the yeast research community using advanced sequencing technology at high quality. We also developed a pipeline for automated pan-genome analysis, which integrates the steps of assembly, annotation, and variation calling. To assign strain-specific functional annotations, we identified genes that were not present in the reference genome. We classified these according to their presence or absence across strains and characterized each group of genes with known functional and phenotypic features. The functional roles of novel genes not found in the reference genome and associated with strains or groups of strains appear to be consistent with anticipated adaptations in specific lineages. As more S. cerevisiae strain genomes are released, our analysis can be used to collate genome data and relate it to lineage-specific patterns of genome evolution. Our new tool set will enhance our understanding of genomic and functional evolution in S. cerevisiae, and will be available to the yeast genetics and molecular biology community.
Guidelines for the use and interpretation of assays for monitoring autophagy. - Autophagy
In 2008 we published the first set of guidelines for standardizing research in autophagy. Since then, research on this topic has continued to accelerate, and many new scientists have entered the field. Our knowledge base and relevant new technologies have also been expanding. Accordingly, it is important to update these guidelines for monitoring autophagy in different organisms. Various reviews have described the range of assays that have been used for this purpose. Nevertheless, there continues to be confusion regarding acceptable methods to measure autophagy, especially in multicellular eukaryotes. A key point that needs to be emphasized is that there is a difference between measurements that monitor the numbers or volume of autophagic elements (e.g., autophagosomes or autolysosomes) at any stage of the autophagic process vs. those that measure flux through the autophagy pathway (i.e., the complete process); thus, a block in macroautophagy that results in autophagosome accumulation needs to be differentiated from stimuli that result in increased autophagic activity, defined as increased autophagy induction coupled with increased delivery to, and degradation within, lysosomes (in most higher eukaryotes and some protists such as Dictyostelium) or the vacuole (in plants and fungi). In other words, it is especially important that investigators new to the field understand that the appearance of more autophagosomes does not necessarily equate with more autophagy. In fact, in many cases, autophagosomes accumulate because of a block in trafficking to lysosomes without a concomitant change in autophagosome biogenesis, whereas an increase in autolysosomes may reflect a reduction in degradative activity. Here, we present a set of guidelines for the selection and interpretation of methods for use by investigators who aim to examine macroautophagy and related processes, as well as for reviewers who need to provide realistic and reasonable critiques of papers that are focused on these processes. These guidelines are not meant to be a formulaic set of rules, because the appropriate assays depend in part on the question being asked and the system being used. In addition, we emphasize that no individual assay is guaranteed to be the most appropriate one in every situation, and we strongly recommend the use of multiple assays to monitor autophagy. In these guidelines, we consider these various methods of assessing autophagy and what information can, or cannot, be obtained from them. Finally, by discussing the merits and limits of particular autophagy assays, we hope to encourage technical innovation in the field.
Small Molecule c-jun-N-terminal Kinase (JNK) Inhibitors Protect Dopaminergic Neurons in a Model of Parkinson's Disease. - ACS chemical neuroscience
There are currently no drugs to treat neurodegeneration in Parkinson's disease (PD) and all existing medications only treat symptoms, lose efficacy over time, and produce untoward side effects. In the current work, we report the first highly selective, orally bioavailable, c-jun-N-terminal kinase (JNK) inhibitor for protection of dopaminergic neurons in vitro and in vivo. At 300 nM this compound showed statistically significant protection of primary dopaminergic neurons exposed to 1-methyl-4-phenylpyridinium (MPP(+)), had pharmacokinetic properties in rodents consistent with twice daily (b.i.d.) dosing, and was orally efficacious at 30 mg/kg in a mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) model of Parkinson's disease. Moreover, a dose-dependent target modulation of c-jun phosphorylation served as a biomarker for demonstrating on-target inhibition of JNK as the mechanism of action for this compound. Collectively these results suggest that this JNK inhibitor could be a promising therapeutic neuroprotective agent in the treatment of Parkinson's disease.
Reliability assessment of a coding scheme for the physical risk factors of work-related musculoskeletal disorders. - Scandinavian journal of work, environment & health
This study assessed the reliability of a novel coding scheme for physical risk factors for musculoskeletal disorders reported to an occupational surveillance scheme.Since 1997 new cases of musculoskeletal disease have been reported as part of a surveillance scheme by over 300 consultant rheumatologists in the United Kingdom; the rheumatologists also gave a short description of the tasks and activities they considered to be causal. With the use of a summary of the activities described, a coding scheme was developed comprising 16 categories of task codes and another 16 categories of movement codes. Four reviewers coded the work activities independently for 576 cases. The fourth rater coded the cases twice. With the use of a single summary kappa statistic and the matrix of kappa coefficients, both interrater reliability and intrarater reliability were assessed.The overall interrater agreement on the task codes was good (kappa = 0.73), with the best agreement for keyboard work (kappa = 0.96) and the worst for assembly work (kappa = 0.40, kappa = 0.37). The interrater agreement on movement codes was also good (kappa = 0.79), with the best agreement for kneeling (kappa = 0.94) and the worst for materials handling (kappa = 0.10). The intrarater agreement was somewhat better than the interrater agreement with both codes.The results suggest that the coding scheme was, on the whole, reliable for classifying the physical risk factors reported as causal.
Relief of severe hyperacusis and diplacusis in a deafened ear by cochlear labyrinthectomy. - The Journal of laryngology and otology
A professional musician with intolerable hyperacusis and dysharmonic diplacusis in a severely deafened ear was successfully relieved of his symptoms by deliberate destruction of the cochlea.

Map & Directions

800 Rose St C-246 Lexington, KY 40536
View Directions In Google Maps

Nearby Doctors

University Health Service 830 South Limestone Street
Lexington, KY 40536
859 235-5511
800 Rose St # Ms 471
Lexington, KY 40536
248 543-3120
800 Rose Street University Of Kentucky College Of Dentistry
Lexington, KY 40536
859 571-1494
Uk Division Of Cardiology 900 S. Limestone, Ctw 320
Lexington, KY 40536
859 230-0295
800 Rose St Hx-302 Ukmc
Lexington, KY 40536
859 574-4457
800 Rose St
Lexington, KY 40536
205 990-0478
University Of Kentucky & Affiliates 800 Rose St., C236
Lexington, KY 40536
859 571-1000
Ukmc General Surgery 800 Rose St.
Lexington, KY 40536
859 236-6346
740 S Limestone St K512
Lexington, KY 40536
859 238-8178